LOS ANGELES, CA, March 20, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"),
Alan Collier, Endonovo’s Chief Executive Officer, stated "We are pleased to announce our partnership with SunMED Medical Solutions (“SunMED”). SunMED is one of the premier medical equipment distributors and claims experts in the country. SunMED successfully submits and is paid for tens of thousands of in-home medical equipment claims each year. This new relationship significantly expands the distribution capacities of Endonovo and well as expands the ability of our medical providers, their facilities and ultimately, our patients to seek medical reimbursement from the healthcare insurance community.
SunMED is a Medicare and Medicaid provider. The Company holds more than 200 insurance contracts and is a Medicaid provider in over 20 states across the country. This well established healthcare company brings to our relationship over 17 years of experience and expertise serving the needs of patients with their personal in-home services. SunMED has become a nationally-recognized leader in Lymphedema support, as well as providing segment-leading services in complex areas such as negative pressure wound care, light therapy, external cochlear sound processors and breast/mastectomy services. We believe Endonovo’s SofPulse product will fit perfectly into SunMED’s distribution channels.”
“In addition to having a large network throughout the United States, I came to know and appreciate the method in which SunMED operates, more specifically their live support. They have designed a system to simplify the upfront order process by connecting directly to customer service agents to work with therapists and to guide patients through the ordering and claims process. We believe this process emulates the same principals Endonovo operates under, which is to make a patients experience easy, informative and customer friendly,” concluded Mr. Collier.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com